{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:25:15Z","timestamp":1782512715651,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1007\/s11897-005-0011-5","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T05:23:30Z","timestamp":1180070610000},"page":"65-71","source":"Crossref","is-referenced-by-count":18,"title":["The risks and benefits of aldosterone antagonists"],"prefix":"10.1007","volume":"2","author":[{"given":"Domenic A.","family":"Sica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"11_CR1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11906-004-0069-6","volume":"6","author":"WH Frishman","year":"2004","unstructured":"Frishman WH, Stier CT: Aldosterone and aldosterone antagonism in systemic hypertension. Curr Hypertens Rep 2004, 6:195\u2013200.","journal-title":"Curr Hypertens Rep"},{"key":"11_CR2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/01.HDX.0000061698.20666.aa","volume":"5","author":"CT Stier","year":"2003","unstructured":"Stier CT, Koenig S, Lee DY, et al.: Aldosterone and aldosterone antagonism in cardiovascular disease. Heart Dis 2003, 5:102\u2013118.","journal-title":"Heart Dis"},{"key":"11_CR3","first-page":"52","volume":"61","author":"F Mantero","year":"2000","unstructured":"Mantero F, Lucarelli G: Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol (Paris) 2000, 61:52\u201360.","journal-title":"Ann Endocrinol (Paris)"},{"key":"11_CR4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/106002809002400112","volume":"24","author":"HA Skluth","year":"1990","unstructured":"Skluth HA, Gums JG: Spironolactone: a re-examination. DICP 1990, 24:52\u201359.","journal-title":"DICP"},{"key":"11_CR5","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2165\/00003495-200363190-00001","volume":"63","author":"D Liew","year":"2003","unstructured":"Liew D, Krum H: Aldosterone receptor antagonists for hypertension. Drugs 2003, 63:1963\u20131972.","journal-title":"Drugs"},{"key":"11_CR6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709\u2013717.","journal-title":"N Engl J Med"},{"key":"11_CR7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309\u20131321.","journal-title":"N Engl J Med"},{"key":"11_CR8","doi-asserted-by":"crossref","first-page":"17A","DOI":"10.1016\/0002-9149(93)90240-D","volume":"71","author":"DA Duprez","year":"1993","unstructured":"Duprez DA, Bauwens FR, De Buyzere ML, et al.: Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1993, 71:17A-20A.","journal-title":"Am J Cardiol"},{"key":"11_CR9","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/0002-9149(93)90807-O","volume":"71","author":"DA Duprez","year":"1993","unstructured":"Duprez DA, De Buyzere ML, De Backer T, et al.: Influence of systemic arterial blood pressure and nonhemodynamic factors on the brachial artery pulsatility index in mild to moderate essential hypertension. Am J Cardiol 1993, 71:350\u2013353.","journal-title":"Am J Cardiol"},{"key":"11_CR10","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","volume":"82","author":"K Swedberg","year":"1990","unstructured":"Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990, 82:1730\u20131736.","journal-title":"Circulation"},{"key":"11_CR11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/01.CIR.103.1.72","volume":"103","author":"Y Mizuno","year":"2001","unstructured":"Mizuno Y, Yoshimura M, Yasue H, et al.: Aldosterone production is activated in failing ventricle in humans. Circulation 2001, 103:72\u201377.","journal-title":"Circulation"},{"key":"11_CR12","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1161\/01.HYP.0000015905.27598.E9","volume":"39","author":"N Yamamoto","year":"2002","unstructured":"Yamamoto N, Yasue H, Mizuno Y, et al.: Aldosterone is produced from ventricles in patients with essential hypertension. Hypertension 2002, 39:958\u2013962.","journal-title":"Hypertension"},{"key":"11_CR13","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","volume":"63","author":"ER Blasi","year":"2003","unstructured":"Blasi ER, Rocha R, Blomme EAG, et al.: Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003, 63:1791\u20131800.","journal-title":"Kidney Int"},{"key":"11_CR14","first-page":"893","volume":"120","author":"CG Brilla","year":"1992","unstructured":"Brilla CG, Weber KT: Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992, 120:893\u2013901.","journal-title":"J Lab Clin Med"},{"key":"11_CR15","first-page":"H1802","volume":"283","author":"AE Rudolph","year":"2002","unstructured":"Rudolph AE, Frierdich GE, Nachowiak DA, et al.: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol 2002, 283:H1802-H1810.","journal-title":"Am J Physiol"},{"key":"11_CR16","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","volume":"141","author":"R Rocha","year":"2000","unstructured":"Rocha R, Stier Jr CS, Kifor I, et al.: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141:3871\u20133878.","journal-title":"Endocrinology"},{"key":"11_CR17","first-page":"E883","volume":"271","author":"MJ Young","year":"1996","unstructured":"Young MJ, Funder JW: The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Am J Physiol 1996, 271:E883-E888.","journal-title":"Am J Physiol"},{"key":"11_CR18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.1973.03220280028007","volume":"225","author":"DJ Greenblatt","year":"1973","unstructured":"Greenblatt DJ, Koch-Weser J: Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program. JAMA 1973, 225:40\u201343.","journal-title":"JAMA"},{"key":"11_CR19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","volume":"217","author":"SM Garthwaite","year":"2004","unstructured":"Garthwaite SM, McMahon EG: The evolution of aldosterone antagonists. Mol Cell Endocrinol 2004, 217:27\u201331.","journal-title":"Mol Cell Endocrinol"},{"key":"11_CR20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mce.2003.10.008","volume":"217","author":"J Menard","year":"2004","unstructured":"Menard J: The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol 2004, 217:45\u201352.","journal-title":"Mol Cell Endocrinol"},{"key":"11_CR21","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1124\/dmd.30.12.1344","volume":"30","author":"CS Cook","year":"2002","unstructured":"Cook CS, Berry LM, Kim DH, et al.: Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. Drug Metab Dispos 2002, 30:1344\u20131351.","journal-title":"Drug Metab Dispos"},{"key":"11_CR22","doi-asserted-by":"crossref","unstructured":"Sica DA: Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 2005, In press.","DOI":"10.1007\/s10741-005-2345-1"},{"key":"11_CR23","first-page":"1331","volume":"22","author":"DS Tolbert","year":"2002","unstructured":"Tolbert DS, Reid SE, Roniker B: Pharmacokinetics of eplerenone coadministered with other medications. Pharmacotherapy 2002, 22:1331.","journal-title":"Pharmacotherapy"},{"key":"11_CR24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/00498250310001649341","volume":"34","author":"CS Cook","year":"2004","unstructured":"Cook CS, Berry LM, Burton E: Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data. Xenobiotica 2004, 34:215\u2013228.","journal-title":"Xenobiotica"},{"key":"11_CR25","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","volume":"76","author":"CS Barr","year":"1995","unstructured":"Barr CS, Lang CC, Hanson J, et al.: Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995, 76:1259\u20131265.","journal-title":"Am J Cardiol"},{"key":"11_CR26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-8278(03)00188-0","volume":"39","author":"J Santos","year":"2003","unstructured":"Santos J, Planas R, Pardo A, et al.: Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol 2003, 39:187\u2013192.","journal-title":"J Hepatol"},{"key":"11_CR27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/00365529850171099","volume":"33","author":"N Ljubicic","year":"1998","unstructured":"Ljubicic N, Kujundzic M, Banic M, Vrkljan M: Predictive factors influencing the therapeutic response to diuretic treatment of ascites in nonazotemic cirrhotic patients. Scand J Gastroenterol 1998, 33:441\u2013447.","journal-title":"Scand J Gastroenterol"},{"key":"11_CR28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/cpt197925133","volume":"25","author":"G Schrijver","year":"1979","unstructured":"Schrijver G, Weinberger MH: Hydrochlorothiazide and spironolactone in hypertension. Clin Pharmacol Ther 1979, 25:33\u201342.","journal-title":"Clin Pharmacol Ther"},{"key":"11_CR29","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/clpt.1980.75","volume":"27","author":"LE Ramsay","year":"1980","unstructured":"Ramsay LE, Hettiarachchi J, Fraser R, Morton JJ: Amiloride, spironolactone, and potassium chloride in thiazide-treated hypertensive patients. Clin Pharmacol Ther 1980, 27:533\u2013543.","journal-title":"Clin Pharmacol Ther"},{"key":"11_CR30","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"MK Nishizaka","year":"2003","unstructured":"Nishizaka MK, Zaman MA, Calhoun DA: Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925\u2013930.","journal-title":"Am J Hypertens"},{"key":"11_CR31","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0895-7061(01)02342-1","volume":"15","author":"J Ouzan","year":"2002","unstructured":"Ouzan J, Perault C, Lincoff AM, et al.: The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002, 15:333\u2013339.","journal-title":"Am J Hypertens"},{"key":"11_CR32","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, Weiss RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002, 15:709\u2013716.","journal-title":"Am J Hypertens"},{"key":"11_CR33","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","volume":"60","author":"X Jeunemaitre","year":"1987","unstructured":"Jeunemaitre X, Chatellier G, Kreft-Jais C, et al.: Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987, 60:820\u2013825.","journal-title":"Am J Cardiol"},{"key":"11_CR34","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/0003-4819-87-4-398","volume":"87","author":"K Rose","year":"1977","unstructured":"Rose K, Underwood RH, Newmark SR, et al.: Pathophysiology of spironolactone-induced gynecomastia. Ann Intern Med 1977, 87:398\u2013403.","journal-title":"Ann Intern Med"},{"key":"11_CR35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0022-4731(89)90169-6","volume":"32","author":"M Gasparo de","year":"1989","unstructured":"de Gasparo M, Whitebread SE, Preiswerk G, et al.: Antialdosterones: incidence and prevention of sexual side-effects. J Steroid Biochem 1989, 32:223\u2013227.","journal-title":"J Steroid Biochem"},{"key":"11_CR36","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"B Pitt","year":"2003","unstructured":"Pitt B, Reichek N, Willenbrock R, et al.: Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003, 108:1831\u20131838.","journal-title":"Circulation"},{"issue":"Suppl 1","key":"11_CR37","doi-asserted-by":"crossref","first-page":"A24","DOI":"10.1016\/S0895-7061(02)02333-6","volume":"15","author":"M Epstein","year":"2002","unstructured":"Epstein M, Buckalew V, Martinez F, et al.: Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone\/enalapril combination in diabetic hypertensives with microalbuminuria. Am J Hypertens 2002, 15(Suppl 1):A24.","journal-title":"Am J Hypertens"},{"key":"11_CR38","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.amjcard.2004.01.007","volume":"93","author":"GH Williams","year":"2004","unstructured":"Williams GH, Burgess E, Kolloch RE, et al.: Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004, 93:990\u2013996.","journal-title":"Am J Cardiol"},{"key":"11_CR39","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1464-5491.2004.01194.x","volume":"21","author":"R Rachmani","year":"2004","unstructured":"Rachmani R, Slavachevsky I, Amit M, et al.: The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 2004, 21:471\u2013475.","journal-title":"Diabet Med"},{"key":"11_CR40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjhyper.2004.06.029","volume":"18","author":"A Sato","year":"2005","unstructured":"Sato A, Hayashi K, Saruta T: Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005, 18:44\u201349.","journal-title":"Am J Hypertens"},{"key":"11_CR41","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1291\/hypres.25.837","volume":"25","author":"A Sato","year":"2002","unstructured":"Sato A, Hayashi M, Saruta T: Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res 2002, 25:837\u2013842.","journal-title":"Hypertens Res"},{"key":"11_CR42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS, et al.: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004, 351:543\u2013551. This is a description of the increase in hospitalization rate for hyperkalemia with the increased use of spironolactone since RALES.","journal-title":"N Engl J Med"},{"key":"11_CR43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1527-5299.2004.02814.x","volume":"10","author":"DA Sica","year":"2004","unstructured":"Sica DA, Hess M: Aldosterone receptor antagonism: interface with hyperkalemia in heart failure. Congest Heart Fail 2004, 10:259\u2013264. This is a comprehensive discussion of factors increasing the risk for developing significant hyperkalemia in HF and treatment strategies to prevent its occurrence.","journal-title":"Congest Heart Fail"},{"key":"11_CR44","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","volume":"78","author":"The RALES Investigators","year":"1996","unstructured":"The RALES Investigators: Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996, 78:902\u2013907.","journal-title":"Am J Cardiol"},{"issue":"Suppl 1","key":"11_CR45","doi-asserted-by":"crossref","first-page":"A100","DOI":"10.1016\/S0895-7061(03)00335-2","volume":"16","author":"DA Sica","year":"2003","unstructured":"Sica DA: Eplerenone and serum potassium change--relationship to renal function. Am J Hypertens 2003, 16(Suppl 1):A100.","journal-title":"Am J Hypertens"},{"key":"11_CR46","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ahj.2004.10.005","volume":"148","author":"KP Tamarisa","year":"2004","unstructured":"Tamarisa KP, Aaronson KD, Koelling TM: Spironolactoneinduced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 2004, 148:971\u2013978.","journal-title":"Am Heart J"},{"key":"11_CR47","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0002-9149(02)02580-8","volume":"90","author":"DA Blaustein","year":"2002","unstructured":"Blaustein DA, Babu K, Reddy A, et al.: Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade. Am J Cardiol 2002, 90:662\u2013663.","journal-title":"Am J Cardiol"},{"key":"11_CR48","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cardfail.2003.10.012","volume":"10","author":"M Svensson","year":"2004","unstructured":"Svensson M, Gustafsson F, Galatius S, et al.: How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 2004, 10:297\u2013303.","journal-title":"J Card Fail"},{"key":"11_CR49","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0735-1097(02)02694-3","volume":"41","author":"B Bozkurt","year":"2003","unstructured":"Bozkurt B, Agoston I, Knowlton AA: Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003, 41:211\u2013214. This paper contains observations that spironolactone is being used widely in HF without consideration of the NYHA class and ejection fraction, and without optimization of background treatment with ACE inhibitors and \u03b2-blockers.","journal-title":"J Am Coll Cardiol"},{"key":"11_CR50","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/archinte.160.11.1605","volume":"160","author":"D Charytan","year":"2000","unstructured":"Charytan D, Goldfarb DS: Indications for hospitalization of patients with hyperkalemia. Arch Intern Med 2000, 160:1605\u20131611.","journal-title":"Arch Intern Med"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-005-0011-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11897-005-0011-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-005-0011-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:09:46Z","timestamp":1559434186000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11897-005-0011-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["11"],"URL":"https:\/\/doi.org\/10.1007\/s11897-005-0011-5","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}